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Intraarterial route increases 
the risk of cerebral lesions after 
mesenchymal cell administration  
in animal model of ischemia
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Mesenchymal stem cells (MSCs) are a promising clinical therapy for ischemic stroke. However, critical 
parameters, such as the most effective administration route, remain unclear. Intravenous (i.v.) and 
intraarterial (i.a.) delivery routes have yielded varied outcomes across studies, potentially due to 
the unknown MSCs distribution. We investigated whether MSCs reached the brain following i.a. or 
i.v. administration after transient cerebral ischemia in rats, and evaluated the therapeutic effects of 
both routes. MSCs were labeled with dextran-coated superparamagnetic nanoparticles for magnetic 
resonance imaging (MRI) cell tracking, transmission electron microscopy and immunohistological 
analysis. MSCs were found in the brain following i.a. but not i.v. administration. However, the i.a. route 
increased the risk of cerebral lesions and did not improve functional recovery. The i.v. delivery is safe 
but MCS do not reach the brain tissue, implying that treatment benefits observed for this route are not 
attributable to brain MCS engrafting after stroke.
Ischemic stroke, caused by interruption of the blood supply to the brain, is one of the most important causes of 
morbidity and mortality worldwide. Currently, the control of systemic parameters, such as body temperature, 
blood pressure, and glycemia, has considerably improved the outcome of stroke patients. However, in the absence 
of protective therapy, an early artery reperfusion, i.e. mechanical or enzymatic thrombolysis, remains the primary 
goal of treatment for acute ischemic stroke1,2.
Cell based therapies have emerged as a promising tool for the treatment of both acute and delayed phases 
of stroke. In this regard, mesenchymal stem cells (MSCs) are one of the best candidates for stem cell therapy of 
ischemic stroke owing to their multipotentiality, ability to release growth factors, and immunomodulatory capac-
ities3. Thus, this transdifferentiation can produce cells with a neural lineage4–7, induce neurogenesis8–10, angio-
genesis8–10 and synaptogenesis11, and activate endogenous restorative processes through production of cytokines 
and trophic factors8,12–14. Moreover, the regulation of cerebral blood flow (CBF), the blood brain barrier (BBB)12, 
and other neuroprotective mechanisms, such as the reduction of apoptosis, inflammation, demyelination, and 
increased astrocyte survival8,9,15,16, have been involved as beneficial mechanisms of MSCs after of stroke3.
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Functional recovery in animal models of focal cerebral ischemia has been observed when MSCs were injected 
intravenously (i.v.) or intraarterially (i.a.)17–20, however, there is not agreement yet about the optimal adminis-
tration route. Intravenous injections are minimally invasive, and cell tracking studies following that route have 
shown that most administered cells remain trapped in the lungs, liver, and spleen21, indicating that a reduced 
number of cells reach the brain22. Intraarterial administration is a promising strategy to direct the majority of 
injected cells to the brain23, but the fate of injected cells following this route remains unknown due to high vari-
ation in the reported results. Indeed, recent studies have shown that approximately 21% of the cells delivered via 
i.a. carotid injection were observed in the ipsilateral hemisphere24. Conversely, other studies have reported that 
24 h after injection, 95% of the delivered cells were found in the spleen25. Additional studies have indicated that 
i.a. carotid cell administration is a safe delivery strategy that can overcome limitations of i.v. administration, since 
it represents a more direct route; however, new findings have associated a higher mortality to i.a. administration 
compared to the i.v. route21. Despite of the discrepancies about the best route for cell administration, it has also 
not been well established if the therapeutic effect described for MCSs after i.a. and i.v. administration requires the 
diffusion of cells through the BBB and the engraftment in the cerebral parenchyma tissue.
Therefore, an in vivo analysis of the cellular fate and biodistribution of both administration routes is an impor-
tant and necessary step towards the further development of minimally invasive stem cell therapy for central 
nervous system diseases, including stroke. To this end, the objective of this study was to perform an analysis of 
cell tagging by magnetic resonance imaging (MRI) contrast agents (CAs) and subsequent MRI analysis to address 
this challenge26.
In this study, first, we synthesized dextran-coated superparamagnetic nanoparticles (D-MNPs), validated 
their use as CAs for cell tracking in MRI, and evaluated the cellular viability of MSCs after labeling, including 
their detection by MRI. Secondly, the optimal route and cell dosage were evaluated for i.a. administration. Third, 
cellular biodistribution patterns following i.a. and i.v. administration were investigated. Finally, the therapeutic 
effects of MSCs administered through either route were compared in an animal model of ischemic stroke.
Results
Synthesis and characterization of D-MNPs. D-MNPs were synthesized in the presence of dextran 
following the chemical co-precipitation method described in the Methods section. Transmission electron 
microscopy (TEM) micrographs (Fig. 1A) showed a mean core size of 3.7 ± 0.8 nm. The core crystal structure 
determined by X-ray diffraction (XRD) (Fig. 1B) showed peaks at 2θ positions of ca. 30.2°, 35.6°, 43.2°, 57.1°, and 
62.7°, corresponding to the (220), (311), (400), (511), and (440) planes of magnetite, respectively, with a lattice 
parameter of 8.33 ± 0.02 Å and a crystallite size of 4.8 ± 0.5 nm derived from the Scherrer equation. Vibrating 
sample magnetometer (VSM) measurements showed that cores exhibited superparamagnetic behavior at room 
temperature (Fig. 1C). The hydrodynamic size of D-MNPs measured by dynamic light scattering (DLS) was 
94 ± 3 nm with Z-potential values of ca. − 11 ± 3 mV. The presence of the polymeric coating was confirmed by 
thermal gravimetric analysis (TGA) and fourier-transform infrared (FTIR). The TGA spectrum (Fig. 1D) showed 
two peaks, corresponding to mass losses at approximately 280 °C and 322 °C, in the range of dextran decompo-
sition temperature (150–380 °C)27, demonstrating that about 66 wt% of the D-MNPs can be attributed to dex-
tran. The FTIR spectrum (Fig. 1E) exhibited several polysaccharide-characteristic absorption bands at 3351 cm−1 
due to O-H stretching; vibrational modes ν (C-H) and δ (C-H) corresponding to 2906 cm−1, 1420 cm−1, and 
1380 cm−1; water molecular bending assigned to 1620 cm−1, 1145 cm−1; and 1010 cm−1 peaks due to C-O vibra-
tions; and small peaks at 908 cm−1, 877 cm−1, and 746 cm−1, corresponding to α -glucopyranose ring deforma-
tion modes. There were also two absorption bands at 578 cm−1 and 430 cm−1, corresponding to Fe-O vibration 
modes28,29. MRI contrast in T2-weighted images at different Fe concentrations (0.09 mmol/L; 0.05 mmol/L, and 
0.02 mmol/L) of D-MNPs were measured (Fig. 1F). A linear relationship was found between R2(R2 = 1/T2) and 
MNP concentration, resulting in a transverse relaxivity (r2) of 701 ± 16 L mmol−1 s−1.
Characterization of mesenchymal stem cells labeling with D-MNPs. The analysis of the cell prop-
erties showed that D-MNP labeling did not reduce the proliferation rate of MSCs with respect to the control 
when evaluated as cell counts at P0 (12 h), P1 (2 days), and P2 (5 days) after labeling (Fig. 2A). No significant 
differences were observed between D-MNPs and the control in terms of cell viability determined by lactate dehy-
drogenase (LDH) assay (Fig. 2A). Vascular endothelial growth factor (VEGF) release was not affected by D-MNP 
internalization with respect to control cells (Fig. 2A) at the different time-points analyzed (P0, P1, and P2). The 
amount of internalized iron oxide nanoparticles was determined in labeled cells by inductive coupled plasma 
optical emission spectroscopy (ICP-OES) (Fig. 2A). Internalized iron at P0 was 7.7 ± 0.7 pg Fe/cell, decreasing to 
2.4 ± 0.2 pg Fe/cell at P1, and 0.90 ± 0.09 pg Fe/cell at P2. MRI analysis of labeled cells and non-labeled cells was 
also performed. T2*-maps were calculated from T2*-weighted images. R2* relaxivities of 500 cells/μ L in agar were 
obtained for each condition (Fig. 2A). At P0, the R2* values were 36.0 ± 1.2 s−1 and 68.0 ± 0.9 s−1 for the control 
and D-MNPs, respectively; at P1, these values were 21 ± 4 s−1 and 31.8 ± 1.1 s−1 for the control and D-MNPs, 
respectively; and at P2, these values were 19 ± 2 s−1 and 19.6 ± 0.8 s−1 for the control and D-MNPs, respectively, 
according to the decrease in internalized iron observed at the different timepoints. Transmission electron micros-
copy (TEM) images of labeled MSCs showed D-MNPs engulfed in cellular compartments and distributed along 
the cell (Fig. 2B). No D-MNPs were observed attached at the surface of the cells. In addition, the matrigel assay 
did not show differences in angiogenic capacity between control and D-MNP-labeled cells at P0 and P2 in terms 
of ring formation and distribution (Fig. 2C). Finally, flow cytometry analysis revealed no differences in the mem-
brane phenotype markers of MSCs (CD90+ , CD73+ and CD45− ) between D-MNPs and non-labeled MSCs at 
P0 and P2 (Fig. 2D). No differences between cell passages 9 and 17 were observed regarding to VEGF release, 
ring formation or membrane phenotype markers. Moreover, analysis of labeled cells with increasing amounts of 
D-MNPs did not affect cellular size (size average in suspension 15 ± 2 μ m).
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Intra-arterial cell tracking of D-MNPs MSCs. To optimize i.a. cell delivery, previously we tested various 
combinations of surgical procedures in an animal model of cerebral ischemia as it is detailed in Fig. 3. In all the 
Figure 1. Characterization of D-MNPs. (A) TEM micrograph showing the morphology and size distribution of 
D-MNP cores; (B) The XRD spectrum of D-MNP cores synthesized through chemical co-precipitation shows the 
characteristic peaks of magnitude at 2θ positions of ca. 30.2°, 35.6°, 43.2°, 57.1°; and 62.7°; (C) Magnetization curve 
of D-MNPs demonstrates superparamagnetic behavior at room temperature; (D) TGA spectrum of D-MNPs and 
(E) FTIR spectrum of D-MNPs provide evidence for the presence of dextran in the D-MNP formulation; (F) T2-
weighted MRI of 0.09 mM, 0.05 mM, and 0.02 mM D-MNPs. Iron concentrations demonstrate the suitability of 
D-MNPs as contrast agents (CA) for MRI analysis.
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Figure 2. Time elapsed study of MSCs labeled with D-MNPs. (A) Cell count after labeling at P0, P1, and P2 
compared to the control. Viability after labeling at P0, P1, and P2 compared to the control as determined by 
LDH assay. VEGF secretion of D-MNPs and the control at P0, P1, and P2. Iron content per cell at P0, P1, and 
P2, as determined by ICP. Relaxation times (R2*) of labeled and non-labeled cells at P0, P1, and P2. T2*-maps 
of control and D-MNP labeled cells at P0, P1, and P2. (B) TEM of a MSC labeled with D-MNPs appearing 
as dispersed black regions within the cellular cytoplasm. Magnification in one region indicates evidence of 
D-MNP encapsulation in endosomes. (C) Matrigel-angiogenic assay in Control and D-MNP labeled MSCs at 
P0 and P2. (D) Flow cytometry analysis of Control and D-MNP-labeled MSCs at P0 and P2 for CD90/CD73/
CD45 analysis. P0 (12 h), P1 (3 days) and P2 (5 days) after D-MNP labeling.
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experimental conditions MSC administration (1 × 106 MNP labeled MSCs suspended in 300 μ L) was carried out 
4 hours after transient middle cerebral artery occlusion (tMCAo).
In administration protocol A (Fig. 3A), a high variation was observed in cerebral MSC detection. MSC admin-
istration following procedure A resulted in brain engraftment in only 3 out of 8 animals, and no associations 
with mortality were found. In this procedure, the ipsilateral common carotid (Ip-CC) remained closed from the 
beginning of tMCAo that could limit the entrance of labeled cells after i.a. administration.
To overcome this effect, in protocol B (Fig. 3B), cerebral blood flow in the Ip-CC was reestablished at the time 
of administration. In this experimental condition, the Ip-CC was opened during the injection, ensuring high 
engraftment efficiency, but most of the animals died (6 out of 8 rats died within 24 h of cell delivery). This high 
mortality could be due to secondary intracerebral hemorrhage since the Ip-CC was closed for 4 h prior to injec-
tion, which could induce vessel damage.
Figure 3. Several combinations of i.a. MSCs delivery were considered in this study to elucidate the most 
efficient and safe administration, here the schemes of different experimental procedures for tMCAo and i.a. 
cannulation for brain stem cell delivery. Black arrows denote differences between the indicated case and the 
previous case. CASE A: The Ip-CC and Con-CC were closed during tMCAo; immediately after reperfusion of 
the MCA, the con-CC was also reperfused. MSCs were administered after 4 h through the Ip-EC with the Ip-CC 
closed. After administration, the Ip-EC and Ip-CC remained closed. CASE B: The Ip-CC and Con-CC were 
closed during tMCAo; immediately after reperfusion of the MCA, the con-CC was perfused as well. MSCs were 
administered after 4 h through the Ip-EC with the Ip-CC opened. After administration, the Ip-EC remained 
closed, while the Ip-CC remained open. CASE C: The Ip-CC and Con-CC were closed during tMCAo; 
immediately following reperfusion of the MCA, both CCs were perfused. MSCs were administered after 4 h 
later through the Ip-EC with the Ip-CC opened. After administration, the Ip-EC remained closed and the Ip-CC 
remained open. CASE D: The Con-CC remained intact during all procedures. Immediately after reperfusion 
of the MCA, the con-CC was reperfused as well. MSCs were administered after 4 h through the Ip-EC with 
the Ip-CC opened. After administration, the Ip-EC remained closed, while the Ip-CC remained open. See 
Supplemental Figure S1 for arterial nomenclature. N = 8 per experimental case. The figure was produced, in 
part, by using Servier Medical Art, (www.servier.com/Powerpoint-image-bank).
www.nature.com/scientificreports/
6Scientific RepoRts | 7:40758 | DOI: 10.1038/srep40758
In protocol C (Fig. 3C), the Ip-CC was opened after tMCAo to prevent the possible vessel damage caused by 
prolonged occlusion. Under these conditions, all the animals showed hypointense signals in MRI, but exhibited 
difficulties in breathing when they awoke from anesthesia, and 4 out of 8 rats died within the next 5 days. Coronal 
MR T2*-weighted images showed dispersed cells along the forebrain and also in the cerebellum suggesting cell 
trafficking through the posterior communicating artery, which connects the vertebro-basilar system with the 
carotid system (diagram of cerebrovascular anatomy is represented in the Supplementary Figure S1).
After occlusion of both common carotids (Fig. 3A–C), blood flow to the forebrain is provided by the 
vertebro-basilar system through the posterior communicating arteries, which suffer vasodilatation. After cell 
injection and under these conditions, the regional localization of cells along the brain and cerebellum depends on 
the CBF distribution in the circle of Willis. To test whether blood supply through the common carotid (Con-CC) 
could prevent cell migration towards the cerebellum, in protocol D (Fig. 3D) this artery was not closed during 
tMCAo. The results showed uniform cerebral cell distribution and no mortality. Typical brain engraftment of 
D-MNP labeled MSCs could be observed in T2*-weighted images (Fig. 4A) after this delivery route. All these 
results are summarized in the Supplemental Table S1.
Figure 4. (A) First echo of MR T2* weighted image of one brain slice of a Wistar rat 8 h after the onset of 
cerebral ischemia, and 4 h after i.a. administration of 1 × 106 MSCs labeled with D-MNPs in case D. Labeled 
cells can be observed as black punctate patterns in the right hemisphere of the animal. (B) Cerebral blood flow 
in three regions of the middle cerebral artery determined in healthy animals by 3 Doppler probes before, during, 
and after administration of PBS, 0.25 × 106 non-labeled MSCs, and 1 × 106 non-labeled MSCs; MR T2-weighted 
images of several brain slices 24 h after cell delivery. Multifocal ischemia is observed all along the brain after 
administration of 1 × 106 MSCs (indicated with yellow arrows). After the administration of 0.25 × 106 MSCs, 
an isolated micro-ischemia was observed in one animal (indicated with a yellow arrow). No edema (middle line 
shift) was observed for all conditions studied. N = 6 per experimental group.
www.nature.com/scientificreports/
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To determine the safety of different cell doses in i.a. administration procedure D, two cell doses, 0.25 × 106 and 
1 × 106 non-labeled MSCs in PBS (used as the cell vehicle) were injected in healthy animals and were compared 
to vehicle administration. CBF was monitored during delivery, and brain was evaluated 24 h after administration 
by MR T2-weighted images. MR images showed absence of lesions in the cerebral tissue of rats receiving PBS 
(Fig. 4B). In contrast, administration of 1 × 106 MSCs induced multifocal lesions in all brain slices (Fig. 4B), and 
injection of 0.25 × 106 MSCs produced only one isolated lesion in one of the animals without evidence of brain 
edema. Multifocal lesions caused by the 1 × 106 dose of MSCs were also associated with a reduction of CBF deter-
mined by laser Doppler flowmetry. Accordingly, we limited the cell delivery in this study to 0.25 × 106 MSCs as a 
safe dose for i.a. administration.
To further study the distribution of MSCs and to determine the possible cause of multifocal lesions observed 
previously, healthy animals were treated (procedure D) with 1 × 106 MSCs labeled with D-MNPs and CFSE (Cell 
Proliferation Kit is used for in vivo labeling of cells) for MRI and histology detection, respectively. T2*-weighted 
images showed D-MNPs labeled MSCs in the brain of all animals. Immunohistological analysis revealed positive 
staining for nuclei (Hoechst), MSCs (CFSE), and vessels (CD31) mainly in the ipsilateral hemisphere along all 
cerebral sections. CFSE positive MSCs were mainly observed in small vessels (Fig. 5A,B) but not in wide vessels, 
and we found no evidence of cells extravasated to the brain parenchyma. Immunohistological analysis of lungs 
and heart did not reveal CFSE positive MSCs. In line with these results, TEM analysis showed MSCs in small 
vessels (Fig. 6), however, labeled MSCs were also detected in the brain parenchyma (Fig. 7). MSCs were identified 
readily due to their contrasting cytoplasmic color compared to the surroundings and scattered dark endosomes 
within the cellular membrane. Magnification in one region showed a dark, punctate pattern inside the endosome 
membrane cristae, with similar distribution, size, and morphology to those previously observed in vitro (Fig. 2B). 
Adjacent to the endosomes, mitochondria were also identified by their cristae, demonstrating the viability of 
MSCs after injection.
Intravenous cell tracking of MSCs. Cell tracking after i.v. administration of 1 × 106 MSCs labeled with 
D-MNPs and CFSE showed no cerebral engraftment, noted as hypointensities in MR T2*-weighted images, in any 
of the rats. This in vivo result was confirmed by histological analysis. No positive CFSE staining for MSCs was 
found in the brain and heart by using fluorescence optical microscopy, whereas positive CFSE-labeled cells were 
found to be distributed along the lungs (Supplemental Figure S2).
Neurorecovery study. Once the optimal injection protocol and MSC dosage for safe i.a. administration 
and the distribution of MSCs after i.v. and i.a. delivery in rats were established, we aimed to evaluate the neu-
rorecovery effect produced by i.a. and i.v. administration of MSCs after cerebral ischemia. D-MNP labeled 
MSCs were detected readily in brain by MR T2*-weighted images at 4 h, 24 h, and 3 days after i.a. injection only 
(Supplemental Figure S3). Infarct volume analysis revealed that both administration route did not reduce the 
infarct volume within 14 days after tMCAo, compared to the groups receiving the vehicle. In fact, lesion size sig-
nificantly increased after i.a. delivery of PBS or MSCs with respect to i.v. treatments (Fig. 8A,B). The administra-
tion of MSCs, either i.a. or i.v., did not reduce edema volume in the acute phase of cerebral ischemia. Moreover, a 
significant increase in edema volume was observed 24 h after i.a. administration (*P < 0.05) (Fig. 8C). Functional 
recovery after MSC delivery was also evaluated by the cylinder test, and no significant differences were observed 
between groups (Fig. 8D). Nonetheless, the group of rats receiving i.v. MSCs showed a reduction of the use of 
the impaired forelimb, but the difference did not reach statistical significance compared to the i.v. control group.
The plasma concentrations of VEGF at different time points were below the limit of detection of the ELISA 
assay used in this study. The presence of neural progenitors in the subventricular region was examined with dou-
blecortin (DCX) and Ki-67 immunostaining (Fig. 9A). Co-localization of DCX and Ki-67 was higher for MSC 
administered groups compared to controls, particularly for DCX staining, a marker of neuronal precursor cells 
and immature neurons (Fig. 9A and C). Infarct and peri-infarct regions were examined to evaluate angiogenesis 
through co-localization of CD31 and Ki-67, but no differences in marker staining were observed between groups 
(Fig. 9B and C).
Discussion
MSCs have received special attention in recent years as a promising therapeutic candidate for stroke due to their 
potential multi-mechanistic effects on the damaged brain30. However, parameters such as the therapeutic window 
and cell dosage or administration route are still under discussion31,32. For a better understanding of how stem cell 
therapies can succeed, non-invasive monitoring of cells is required, and MRI is one of the most appropriate tools 
for this use because it provides excellent soft tissue contrast and high resolution33–35. MRI can provide anatomical 
and pathological information and, by tagging cells with MRI CAs such as superparamagnetic nanoparticles, MRI 
can establish the relationship between cellular biodistribution and outcome after stroke.
Indeed, the fate and biodistribution of injected MSCs after stroke is a critical aspect for therapeutic efficacy; 
therefore, the administration route is a decisive parameter. The most common routes of MSC transplantation are 
i.v. or i.a. infusion, or direct intra-tissue injection36. Although intraparenchymal (i.p.) administration provides 
direct cell delivery to the lesion, it results in poor lesion distribution and is highly invasive due to the necessary 
craniotomy23. Many studies have explored i.a. and i.v. administration in animal models of ischemic stroke with 
different degrees of success in terms of outcome37–39 and brain engraftment23,40–42, but only a few have established 
a relationship between them43–45. In this study, we administered MSCs labeled with D-MNPs to address the rela-
tionship between cell allocation and animal recovery after stroke.
Superparamagnetic iron oxide nanoparticles are the most frequently used CAs for cell tracking owing to the 
high hypointense MR signal in T2 and T2*-weighted images at low nanoparticle concentrations46. Several meth-
ods have been described for synthesizing these particles47. However, chemical co-precipitation is the easiest, most 
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economical, and efficient in terms of producing a large amount of nanoparticles48,49. Our synthesis resulted in 
well-coated, size-uniformed, slightly negatively charged and homogeneously dispersed nanoparticle suspensions 
in aqueous solutions, similar to other nanoparticles previously used28,29,50–52. D-MNPs exhibited superparamag-
netic behavior at room temperature, reflecting their suitability as a general MRI CA.
Although these nanoparticles can be used directly as a CA for MRI53–55, in vivo cell tracking requires nano-
particle internalization into the cells, which is a challenging procedure, as both are negatively charged56. To over-
come this pitfall, Poly-L-lysine (PLL) (see methods for cell labeling with D-MNPs) was used because it has been 
widely accepted for nanoparticle cell tagging based on its low toxicity profile and high iron content per cell at low 
incubation concentrations57–61. Indeed, labeling was highly efficient, as particles were found inside the cells when 
observed by TEM, reducing the risk of unspecific contrast and possible MRI misinterpretation59,62. Quantitatively, 
the internalization of D-MNPs at P0 is in accordance with previous studies which have demonstrated the require-
ment of PLL for efficient cell labeling with commercial and in-house-synthesized dextran coated nanoparticles, 
obtaining comparable nanoparticle internalizations, up to 20 pg/cell59,63,64. However, since the administered cells 
Figure 5. Histological cell localization after intraarterial (i.a.) administration of CFSE labeled MSCS. 
Positive staining of injected MSCs can be seen in the small diameter vessels (A and B) but not in big vessels  
(A). CFSE is co-localized with CD31 and Hoechst. (Scale bar 100 μ m).
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must survive and interact with other cells in the host, an in vitro study of long-term detection and stem cell 
biology was necessary. Thus, labeled cells were seeded sequentially at P1 (2days) and P2 (5days), and their inter-
nalized iron and consequently T2*-MRI signals were found to be reduced. However, D-MNP-labeled MSCs were 
still detected by MRI immediately after labeling (P0) and 2 days later (P1). The MRI signal from labeled cells at 
P2 could not be distinguished from the control; the lower detectability limit for labeled cells has been reported 
previously to be 2–5 pg Fe/cell61,65. This dilution factor over time is related to the in vitro proliferation rate of 
MSCs (approximately two cell divisions, each lasting 24 h), which suggests that other cell types with therapeutic 
potential but different proliferation ratios could be labeled for longer or shorter periods of time.
Despite the indispensable MRI detection capacities of D-MNPs, cellular viability after labeling must be guar-
anteed for further effective therapy. One of the most relevant mechanisms of action of MSCs includes the release 
of VEGF, which promotes the development of fibroblasts, endothelial cells, and tissue progenitor cells, and per-
forms tissue regeneration and repair66. In this study, labeled and non-labeled cells secreted equal levels of VEGF 
immediately after labeling and also 5 days after tagging, and MSCs maintained angiogenic capacity for tubular 
formation. Unchanged surface markers CD45−, CD90+, and CD73+ measured by flow cytometry67–70 after 5 days 
support the biocompatible nature of D-MNPs for MSC tagging.
Figure 6. Electron transmission micrograph of rat brain cortex 4 h after intra-arterial (i.a.) delivery of 
D-MNP-labeled MSCs. (A) Dilated brain vessel surrounded by neuropil (Scale bar 5 μ m). (B) Magnification of 
vessel dilation in (A). Red blood (RB) corpuscles are on the right, and platelets(PTs) and MSCs can be observed 
inside the vessel (Scale bar 2 μ m). (C) Magnification of the upper vessel expansion in (B). One well-defined 
MSC is identified by the encapsulated D-MNPs (black punctate encapsulated pattern). (Scale bar 1 μ m).  
(D) Longitudinal section of a brain vessel where two D-MNPs labeled MSCs can be observed. Encapsulated 
D-MNPs are noted by dark punctuate patterns (Scale bar 2 μ m).
Figure 7. Transmission electron micrograph of rat brain cortex 4 h after intra-arterial (i.a.) delivery 
of D-MNP-labeled MSCs. (A) One single MSC labeled with D-MNPs was found in the brain parenchyma 
surrounded by neuropil (NP) (Scale bar 2 μ m). (B) Magnification of the region selected in A, where D-MNPs 
are observed as black punctate regions compartmentalized within a membrane. Three mitochondria (MT) 
can be noted as well (Scale bar 0.5 μ m). (C) One single MSC labeled with D-MNPs was found in the brain 
parenchyma surrounded by neuropil (NP) and by a neuron (NEU) (Scale bar 2 μ m). (D) Magnification of the 
region selected in C, where D-MNPs can be distinguished as black punctate regions compartmentalized within 
the membrane (Scale bar 0.5 μ m).
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The efficient labeling of MSCs in vitro led to the in vivo study of MSC biodistribution after delivery. Several 
studies have reported that the i.a. administration of stem cells is not a trivial issue, with high risk of secondary 
embolisms and high mortality23,25,37,71–77 as we have confirmed in our study. However, despite the risk of second-
ary embolisms, herein we have also observed that relatively small variation in carotid arteries occlusion, during 
tMCAo and i.a. cell administration has an enormous impact on cellular biodistribution and the survival of the 
animals. To our knowledge, this is the first work investigating the influence of the arterial cerebral system on cell 
biodistribution and also provides a tMCAo model for a safe an efficient i.a. cell delivery procedure, potentially 
useful for the administration of labelled MSCs or other types of cells. In brief, after tMCAo, the Ip-CC is perfused 
to prevent hemorrhagic transformation78, and the Con-CC is opened to provide sufficient blood supply to push 
the injected cells to the brain. Thus, labeled cells were observed in the brain of all animals and all survived after 
administration.
Intraarterial administration flow is another important parameter that must be considered to prevent the 
occurrence of micro-strokes in cell therapy. Indeed, previous studies performed in healthy animals79 have sug-
gested that i.a. cell injections should be performed slowly, at a rate of 200 μ L/min (1 mL) to reduce the risks of sec-
ondary embolisms. In our study, we have even observed that a lower rate of 20 μ L/min (300 μ L) cause secondary 
embolisms when the cell dose is higher than 0.25 × 106 cells. Although experimental differences such as surgery 
procedure, surgery time, cell culture protocols, type of anesthesia used, animal blood pressure during cell admin-
istration or even animals strain (Wistar vs Sprague-Dawley) could explain the differences on optimal injection 
rate, both results evidence the risk of secondary embolisms during i.a. cell administration.
To elucidate the cause of cerebral lesions induced by i.a. cell administration and to determine whether the 
injected cells localized in vessels or migrated to the brain parenchyma, the cerebral tissue was analyzed by histol-
ogy. CFSE positive cells were found in small diameter vessels suggesting vessel blockade that could explain why 
i.a. injection induced multifocal ischemia. However, tissue processing for immunofluorescence analysis could 
perturb cell localization since the animals must be perfused to eliminate the blood. On the contrary, TEM does 
not require animal perfusion and D-MNP-labeled MSCs were unequivocally detected because the D-MNPs were 
encapsulated in the cell endosomes. Brain cortex TEM revealed the presence of D-MNP-labeled MSCs occluding 
brain vessels, confirming the optical immunofluorescence observations and the origin of the lesions observed in 
the MR T2-weighted image analysis. In addition, TEM allowed detection of D-MNP-labeled MSCs in the brain 
parenchyma. Isolated MSCs migrated from vessels to the parenchyma, being in direct contact with the neuropil, 
where somas and cellular processes have been observed80.
Figure 8. Neurorecovery after i.a. and i.v. administration of MSCs. (A) Infarct volumes (% hemisphere and 
corrected by edema) measured from MR apparent diffusion coefficient (ADC) (tMCAo) and T2-map (days 1 
to 14). (B) Representative follow-up MRI of each study group (ADC maps images for tMCAo and T2 weight 
images for 1, 3, 7 and 14 days). (C) Edema volume (% increase in ipsilateral hemispheric volume with respect 
to contralateral hemispheric volume). (D) Use of impaired forelimb (%) as determined by cylinder tests (N = 6; 
*P < 0.05).
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Labeled cells were found in the brain parenchyma, evidence that after i.a. administration in a healthy rat, 
MSCs can cross the BBB. Other studies have assessed the capacity of MSCs to cross the BBB in healthy animals as 
well in ischemic stroke, Alzheimer disease, and epileptic animals models81; however, to our knowledge, this is the 
first work that directly demonstrates MSCs in the brain parenchyma in healthy rats.
In this study, the biodistribution of MSCs after i.v. administration was demonstrated to be definitively different 
from that after i.a. delivery. In vivo MRI combined with immunofluorescence analysis showed that after jugular 
administration (i.v.) of CFSE and D-MNP-labeled MSCs, MSCs were retained in the lungs. Although organs like 
liver, spleen or heart are potential organs where cells can be trapped after i.v. administration, several studies have 
described the lungs as the major obstacle for intravenous cell delivery; as a consequence, a reduced proportion of 
injected cells could reach the arterial circulation and thus the brain. Cell size and receptor-mediated adhesion or 
stem cell type appear to be crucial variables for pulmonary stem cell passage22,82.
Figure 9. (A) Immunohistofluorescence of subventricular zones to reveal neurogenesis using DCX and  
Ki-67. Representative images of different groups are shown corresponding to the blue rectangle in the scheme. 
(B) Immunohistofluorescence of peri-infarct region to evaluate the angiogenesis by using CD31 and Ki-67. 
Representative images of the different groups are shown corresponding to the red rectangle in the scheme. 
Scale bar represents 50 μ m. (C) Analyses of positive cells for Ki-67 and CDX or CD31 makers in different brain 
regions of control and treated (i.a. and i.v.) animals. Data are shown as mean ± SEM. **P < 0.01; using two-way 
ANOVA followed by the post-hoc Bonferroni test, (n = 3, per group). The figure was produced, in part, by using 
Servier Medical Art, (www.servier.com/Powerpoint-image-bank).
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More importantly, the finding that no cells were observed in the brain 24 h after administration confirms 
the non-engraftment of MSCs in the brain after i.v. administration, a salient point that has been discussed 
widely23,41,43–45.
In this study, we also examined the therapeutic effect after i.a. and i.v. administration, considering previous 
findings that (1) MSCs can be labeled with D-MNPs without side effects and (2) their biodistribution is depend-
ent upon the route of administration. Our administration window was 4 h after the onset of ischemia, since 
several groups investigating the therapeutic window for stem cell administration in animal models of cerebral 
ischemia have suggested that early intervention could reduce lesion size and improve the functional outcome44,83.
Cells administered for the neurorecovery study were labeled with D-MNPs, and the animals were monitored 
for 14 days. Intraarterial administration of 0.25 × 106 labeled MSCs resulted in detectable brain engraftment 3 
days after delivery, whereas it was not possible to detect labeled cells in brains of animals injected i.v. with 1 × 106 
MSCs during the 14 days of evaluation.
Under our experimental conditions, no significant differences in infarct volume reduction and edema for-
mation were observed for MSCs-treated and non-treated animals; in fact, i.a. delivery produced larger infarct 
volumes and edema formation than control or i.v. administration. A slight improvement in functional recovery 
was observed for i.v. administered cells, although this result did not achieve significance. It could be tentative 
to speculate that additional functional tests could contribute to find higher significant differences between the 
groups studied. However, among the different behavioral or neurological tests used for ischemic animal outcome 
evaluation, in our hands, cylinder test used represents one of most sensitive for functional evaluation of animal 
outcome, for this reason we have used this test as gold standard test for the cell therapy evaluation.
These results are in accordance with previous studies that have reported that stem cell therapies improved 
neurological function recovery without reduction in lesion volume84–86. Parameters such as the animal model, 
dosage, and therapeutic window have been shown to highly influence infarct volume reduction and functional 
recovery39,43,83,84,87.
Favorable effects on behavioral outcomes after an ischemic insult are normally associated with regenerative 
processes in the microenvironment, namely neurogenesis and angiogenesis88–90. Thus, in our study, we deter-
mined that treatment with MSCs significantly increases Ki-67 and DCX immunoreactivity in the ipsilateral sub-
ventricular zone, suggesting that MSC treatment enhances endogenous neurogenesis, but does not differ between 
i.a. and i.v. administration. Neurogenesis was reported previously by other authors following intrathecal and 
intraparenchymal administration of MSCs91,92. On the contrary, CD31 plus Ki-67 did not show an increase in 
angiogenesis in treated animals compared to the control 14 days following cerebral ischemia.
Previous studies have shown that human MSCs administered i.v. in rats after stroke promoted recovery 
through increases in endogenous levels of VEGF, VEGFR2, and basic-fibroblast growth factors93,94. In this study, 
we demonstrated that D-MNP-labeled MSCs secrete equal levels of VEGF compared to non-labeled cells in vitro, 
but MSC administration did not increase blood serum levels sufficiently to be detected in our ELISA assay.
Taken together, our findings indicate that i.v. administration of 1 × 106 MSCs can improve functional out-
come after cerebral ischemia to an extent, which is in agreement with several studies that have shown the remote 
immunomodulatory effects of these cells95,96. In this way, MSCs entrapped in the lung would affect immune 
system function systemically, supporting the hypothesis that beneficial MSC effects after stroke can be achieved 
in the absence of significant MSC recruitment to the infarct region, even overcoming the associated risks that i.a. 
administration represents97. In addition, MSCs after an experimental stroke have been found to secrete a wide 
number of neuroprotective and neurotrophic factors that promote repair and recovery through numerous path-
ways97. These secreted trophic factors would influence the neurogenesis observed 14 days after stroke, as it has 
already been reported3 however, brain engraftment does not seem to be a determinant, since neurogenesis has 
been observed following i.a. and i.v. delivery of MSCs.
Several limitations of this study have to be addressed. We have studied the cellular wellbeing of labeled cells 
for 5 days, but since these cells are aimed to survive and interact with the host cells, a longer-term study on their 
evolution would be necessary. On the other hand, we have chosen 4 hours for i.a and i.v administration after 
ischemia as the optimal therapeutic window for cell therapy based on previous studies44,83, however we cannot 
exclude the possibility that other time windows (shorter or longer than 4 hours), could induce benefic effect for 
i.a. administration. Although, the results reported to date about the optimal-time window for cell therapy are dif-
ficult to compare and still it is not a well-established timing for cell transplantation. Finally, in the neurorecovery 
study we have compared 0.25 × 106 cells for i.a. administration vs 1 × 106 cells for i.v. administration which could 
explain why i.v. route showed a greater effect. In this study we have used a dose of 0.25 × 106 cells for i.a. admin-
istration because this was the safest dose for i.a. For i.v. administration, we have used 1 × 106 because this is the 
most common dose for i.v. administration in rodents and because there are so many studies that have reported 
that doses lower than one million do not have effect on stroke improvement39,43. Therefore we decided to com-
pare the highest and safest cell dose for i.a. vs the minimal and most common i.v. cell dose that could possibly be 
expected to have an effect.
In conclusion, MSCs were found in the brain following i.a. but not i.v. administration in ischemic rats. 
However, the i.a. route increased the risk of cerebral lesions and did not improve functional recovery. The i.v. 
delivery is safe but MCSs do not reach the brain tissue, implying that treatment benefits are not attributable to 
brain MCS engrafting after stroke.
Materials and Methods
Cell labeling with D-MNPs combined with Poly-L-Lysine. MSCs were labeled with D-MNPs follow-
ing the protocol previously described59. See Supplementary Data for additional D-MNP synthesis and cell labe-
ling characterization with D-MNPs.
www.nature.com/scientificreports/
13Scientific RepoRts | 7:40758 | DOI: 10.1038/srep40758
Experimental animals. All procedures involving the use of research animals were approved by the Research 
Committee of the University Clinical Hospital of Santiago de Compostela (Spain) and were performed according 
to the “Principles of Laboratory Animal Care” (NIH publication No. 86–23, revised 1985), as well as specific 
Spanish (RD 1201/2005 and RD 53/2013) and European Union (Directives 86/609/CEE, 2003/65/CE, 2010/63/
EU) regulations.
Male Wistar rats (Harlan Laboratories, Barcelona, Spain) weighing 290 ± 10 g were kept in a controlled envi-
ronment at 22 ± 1 °C and 60 ± 5% humidity, with 12:12 h light: darkness cycles and were fed ad libitum with 
standard diet pellets and tap water. All surgical procedures and MRI studies were conducted under sevoflurane 
(Abbott laboratories, IL, USA) anesthesia (3–4%) using a carrier 65:35 gas mixture of N2O:O2. All animals used 
in the study (included and excluded) are summarized in the Supplemental Figure S4.
Transient ischemic stroke model. Transient focal ischemia (45 min) was induced by intraluminal occlu-
sion of the left middle cerebral artery (tMCAo), following the method described elsewhere98. Briefly, under a 
surgical microscope, the ipsilateral common carotid (Ip-CC), ipsilateral external carotid (Ip-EC), and ipsilateral 
internal carotid (Ip-IC) arteries were exposed and dissected from connective tissue through a midline neck inci-
sion (Supplemental Figure S1). Ip-EC and pterygopalatine (PT) arteries were separated and tied with 6–0 silk 
sutures. In our model, common carotid (Con-CC) was also tied during surgery in order to obtain higher repro-
ducible infarct volumes (see Intra-arterial administration protocol). Then, a silicon rubber-coated monofilament 
(403512PK5Re; Doccol Corporation, Sharon, MA, USA) was inserted through the Ip-EC into the CC artery and 
advanced into the IC to occlude the origin of the MCA. Cerebral blood flow was monitored with a Periflux 5000 
laser-Doppler system (Perimed AB, Sweden) by placing the Doppler probe (model 411, Perimed AB, Sweden) 
in the parietal bone surface near the sagittal crest, under the temporal muscle. Once the artery was occluded, as 
determined by Doppler signal reduction, the anesthetized animals were moved carefully in less than 1 min from 
the surgical bench to a MR, to determine the basal ischemic lesion apparent diffusion coefficient (ADC) maps. 
In addition, angiography imaging was performed to confirm the artery remained occluded during the MR study. 
After basal MR analysis, animals were returned to the surgical bench for subsequent MCA reperfusion (45 min 
after occlusion). After surgery, animals were allowed to wake from anesthesia and to maintain a free moving gait 
until cell administration (4 h after reperfusion). Only animals with a CBF reduction higher than 60% in Doppler, 
MRI angiography validation of MCA occlusion, ADC hemispheric infarct volume ≥ 35 ± 10%, and complete 
reperfusion after MCA occlusion were included in the study.
Intra-arterial administration of MSCs for in vivo cell tracking. The different experimental conditions 
tested for i.a. cell administration required testing the effect of contralateral common carotid (Con-CC) occlusion 
during tMCAo, and Ip-CC occlusion during and after MCAo, (see below in Fig. 3 and Supplemental Table S1). 
Vertebral arteries remained intact during all surgical procedures. Four hours after ischemia, animals were anes-
thetized and 1 × 106 MNP labeled MSCs suspended in 300 μ L of PBS were administered manually and carefully 
(perfusion rate: 20 μ L/min) through the Ip-EC for in vivo cell tracking following the 4 different experimental 
conditions indicated in Fig. 3 (N = 8, each experimental condition). MR T2*-weighted images were acquired 4 h 
after administration to evaluate cellular engraftment in the brain.
For i.a. cell administration, a catheter (polythene tube of 80 cm of length and 0.28 mm ID and 0.61 mm OD 
from Smiths) was introduced 0.3 mm (approx.) in the ECA until the bifurcation of the CC. To avoid cell precipi-
tation in the syringe, syringe was shaking during administration, that forced the use of manual injection instead 
of automatic pump. After cell administration, the catheter was removed and the arteriotomy site was ligated to 
prevent bleeding, the skin was closed, and the animal was allowed to recover from anesthesia.
Intra-arterial administration dosage of MSCs. To determine the optimal cell dosage for i.a. cell admin-
istration, the effect of i.a. injection of two different cell doses on cerebral blood flow (CBF) was evaluated in 
healthy animals. Thus, 0.25 × 106 and 1 × 106 MSCs suspended in 300 μ L PBS and vehicle were administered i.a. 
following the procedure indicated in case D (N = 6, each group). Following same protocol used for cell labeling 
characterization (see Supplemental Information), MSCs were incubated during 24 h with D-MNP, washed an 
incubated again during 12 h. Less than 15 min before animal injection, cells where detached and suspended in 
PBS.
To analyze the impact of cell administration on CBF, three laser Doppler probes were placed onto the squa-
mosal bone in the skull to cover the territory of the MCA, and CFB was monitored prior and during the cell 
injection and for 1 h after administration. Twenty four hours after cell delivery, MR T2-weighted images were 
performed to evaluate the brain. Workflow of cell labeling, cell animal injection and MRI scanning is represented 
in Supplemental Figure S5.
The cell dose and therapeutic window were selected based on previous meta-analysis39.
Biodistribution of MSCs after intra-arterial administration by means of MRI and histological 
analysis. One million CFSE-D-MNP labeled MSCs suspended in 300 μ L PBS were administered i.a. fol-
lowing the procedure indicated in procedure D in healthy animals (N = 6). Four hours after cell delivery, MR 
T2*-weighted images were acquired to evaluate brain engraftment of the cells. Immediately after MRI, animals 
were sacrificed for immunohistological analysis and for transmission electronic microscopy (TEM). A scheme of 
cell labeling, cell animal injection and MRI scanning is represented is showed in Supplemental Figure S5.
Biodistribution of MSCs after intravenous administration. Intravenous (i.v.) administration was 
performed through the jugular vein in healthy animals (N = 6). For that purpose, a 0.5 cm incision was made 
in the animal’s neck just above the clavicle and 1 cm to both the left and right of the midline. Subcutaneous fat 
was cut, the jugular vein was exposed, and 1 × 106 CFSE-D-MNP labeled MSCs suspended in 300 μ L PBS were 
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administered manually using a 30gauge needle. An MRI was performed 4 h after administration to detect MSCs. 
Finally, the animals were sacrificed for further histological analysis immediately after the MRI. Workflow of cell 
labeling, cell animal injection and MRI scanning is represented in Supplemental Figure S5. The cell dose and 
therapeutic window were selected based on previous meta-analyses39.
Neurorecovery study. To evaluate the effect of the administration route (i.a. vs. i.v.) on the neurorecovery 
efficacy of MSCs in stroke animal models, 4 groups were considered: Group 1 (N = 6): tMCAo treated with 300 μ L 
PBS i.v. (jugular vein) 4 h after the onset of ischemia; Group 2 (N = 6): tMCAo treated with 300 μ L 1 × 106 MSCs 
labeled with D-MNPs i.v. (jugular vein) 4 h after the onset of ischemia; Group 3: tMCAo treated with 300 μ L PBS 
i.a (procedure D) 4 h after the onset of ischemia; and Group 4 (N = 6): tMCAo treated with 300 μ L 0.25 × 106 
D-MNP labeled MSCs and PBS i.a. (procedure D) 4 h after the onset of ischemia.
Animals were evaluated by means of infarct volume, functional deficit, blood cytokine levels, and histology 
analysis. Infarct volume sizes were measured using ADC maps, calculated from MR diffusion weighted imag-
ing (DWI) acquired during occlusion (t = 0) to determine the basal ischemic damage before cell administra-
tion, and on T2-maps, obtained from T2-weighted images at days 1, 3, 7, and 14 after the induction of ischemia. 
Infarct volume sizes were expressed as percentages with respect to hemisphere volume corrected by edema factor. 
T2*-weighted images were acquired to track the injected cells and to evaluate hemorrhagic lesions 4 hours, 1, 3, 
7, and 14 days after ischemia. In the Supplemental Figure S5 is showed all procedure for cell labeling, cell ani-
mal injection and MRI scanning. A cylinder test was used to evaluate the functional deficit and was performed 
prior to ischemia to assess the basal locomotor symmetry of the animals and on days 7 and 14 after ischemia. 
Venous blood samples (250 μ L) were also collected during the occlusion 4 and 8 hours and, 1, 3, 7, and 14 days 
after ischemia to obtain further VEGF analysis. Finally, on day 14, animals were transcardially perfused and their 
brains processed for further histology analyses.
Magnetic resonance imaging. MRI studies were conducted on a 9.4 T MR system (Bruker Biospin, 
Ettlingen, Germany) with 440 mT/m gradients. In vitro and in vivo magnetic resonance imaging is described in 
detail in Supplementary Data.
Behavioral cylinder test. Forelimb contacts while rearing were scored with a total of 10 contacts recorded 
for each animal. The number of impaired and non-impaired forelimb contacts was calculated as the percentage of 
total contacts. The cylinder test was performed prior to tMCAo and 7 and 14 days after ischemia.
Histological analysis. Histological analysis of cells location was also performed by means of TEM and 
immunohistology analysis. See Supplementary Data for information about histological protocols.
VEGF analysis in serum samples. Venous blood was collected from the tail vein prior to MCAo, 4, 8 and 
24 h, and 1, 3, 7, and 14 days after the onset of ischemia. Blood serum was obtained and stored at − 80 °C until 
VEGF determination. ELISA assays were performed using a Quantikine ELISA Rat VEGF kit (R&D Systems, Inc., 
MI, USA) following the commercial indications. Detection limits were 31.2 pg/mL.
Statistical analyses. All data were presented as the mean and standard deviation (mean ± SD). Two-way 
analysis of variance (ANOVA) followed by post-hoc Bonferroni evaluation was used for multiple groups to deter-
mine significant differences. Statistical significance was set at P < 0.05. Statistical analyses were conducted using 
IBM SPSS Statistics for Macintosh, version 18.0 (SPSS Inc., IL, USA).
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